Concepedia

Sonal Bordia

SB

7

Publications

918

Citations

7

H-Index

2007

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Samsung Medical Center

University College London

Asan Medical Center

Universidad de La Frontera

Sonal Bordia is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2007–2023

7

Publications

7

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

, , +8

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Hedy L. Kindler, Pascal Hammel, Michele Reni et al. · Journal of Clinical Oncology · 2022 · 200 citations · Full text

KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma

Manish A. Shah, Jaafar Bennouna, Toshihiko Doi et al. · Future Oncology · 2021 · 121 citations · Full text

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Johann S. de Bono, David S.P. Tan, Reece Caldwell et al. · Journal of Clinical Oncology · 2019 · 30 citations

, , +19

Alcohol consumption and blood pressure in the adult US population: assessment of gender-related effects

Samy I. McFarlane, Hans von Gizycki, Moro O. Salifu et al. · Journal of Hypertension · 2007 · 20 citations

Rows per page

1–5 of 7